nitrophenols and ML355

12-lipoxigenase (12-LOX) is implicated in regulation of platelet activation processes and can be a new promising target for antiplatelet therapy. However, investigations of 12-LOX were restricted by the lack of specific and potent 12-LOX inhibitors and by controversial data concerning the role of 12-LOX metabolites in platelet functions. A novel specific 12-LOX inhibitor ML355 was shown to inhibit platelet aggregation without adverse side effects on hemostasis; however, the molecular mechanisms of its action on platelets are poorly understood. Here, we showed that ML355 inhibited platelet activation induced by thrombin or thromboxane A

Topics: Animals; Apoptosis; Biphenyl Compounds; Blood Platelets; Mice; Nitrophenols; Phosphatidylinositol 3-Kinases; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Sulfonamides; Thrombin